Harmonizome 3.0

cellular retinoic acid binding protein 1

This gene encodes a specific binding protein for a vitamin A family member and is thought to play an important role in retinoic acid-mediated differentiation and proliferation processes. It is structurally similar to the cellular retinol-binding proteins, but binds only retinoic acid at specific sites within the nucleus, which may contribute to vitamin A-directed differentiation in epithelial tissue. [provided by RefSeq, Jul 2008]

stimulated by retinoic acid 6

The protein encoded by this gene is a membrane protein involved in the metabolism of retinol. The encoded protein acts as a receptor for retinol/retinol binding protein complexes. This protein removes the retinol from the complex and transports it across the cell membrane. Defects in this gene are a cause of syndromic microphthalmia type 9 (MCOPS9). Several transcript variants encoding a few different isoforms have been found for this gene. [provided by RefSeq, Dec 2008]

retinoic acid receptor, alpha

This gene represents a nuclear retinoic acid receptor. The encoded protein, retinoic acid receptor alpha, regulates transcription in a ligand-dependent manner. This gene has been implicated in regulation of development, differentiation, apoptosis, granulopoeisis, and transcription of clock genes. Translocations between this locus and several other loci have been associated with acute promyelocytic leukemia. Alternatively spliced transcript variants have been found for this locus.[provided by RefSeq, Sep 2010]

retinoic acid receptor, beta

This gene encodes retinoic acid receptor beta, a member of the thyroid-steroid hormone receptor superfamily of nuclear transcriptional regulators. This receptor localizes to the cytoplasm and to subnuclear compartments. It binds retinoic acid, the biologically active form of vitamin A which mediates cellular signalling in embryonic morphogenesis, cell growth and differentiation. It is thought that this protein limits growth of many cell types by regulating gene expression. The gene was first identified in a hepatocellular carcinoma where it flanks a hepatitis B virus integration site. Alternate promoter usage and differential splicing result in multiple transcript variants. [provided by RefSeq, Mar 2014]

retinoic acid receptor, gamma

This gene encodes a retinoic acid receptor that belongs to the nuclear hormone receptor family. Retinoic acid receptors (RARs) act as ligand-dependent transcriptional regulators. When bound to ligands, RARs activate transcription by binding as heterodimers to the retinoic acid response elements (RARE) found in the promoter regions of the target genes. In their unbound form, RARs repress transcription of their target genes. RARs are involved in various biological processes, including limb bud development, skeletal growth, and matrix homeostasis. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Aug 2011]

cellular retinoic acid binding protein 2

This gene encodes a member of the retinoic acid (RA, a form of vitamin A) binding protein family and lipocalin/cytosolic fatty-acid binding protein family. The protein is a cytosol-to-nuclear shuttling protein, which facilitates RA binding to its cognate receptor complex and transfer to the nucleus. It is involved in the retinoid signaling pathway, and is associated with increased circulating low-density lipoprotein cholesterol. Alternatively spliced transcript variants encoding the same protein have been found for this gene.[provided by RefSeq, Dec 2010]

retinoic acid induced 1

This gene is located within the Smith-Magenis syndrome region on chromosome 17. It is highly similar to its mouse counterpart and is expressed at high levels mainly in neuronal tissues. The protein encoded by this gene includes a polymorphic polyglutamine tract in the N-terminal domain. Expression of the mouse counterpart in neurons is induced by retinoic acid. This gene is associated with both the severity of the phenotype and the response to medication in schizophrenic patients. [provided by RefSeq, Jul 2008]

retinoic acid receptor responder (tazarotene induced) 2

This gene encodes a secreted chemotactic protein that initiates chemotaxis via the ChemR23 G protein-coupled seven-transmembrane domain ligand. Expression of this gene is upregulated by the synthetic retinoid tazarotene and occurs in a wide variety of tissues. The active protein has several roles, including that as an adipokine and as an antimicrobial protein with activity against bacteria and fungi. [provided by RefSeq, Nov 2014]

retinoic acid receptor responder (tazarotene induced) 3

Retinoids exert biologic effects such as potent growth inhibitory and cell differentiation activities and are used in the treatment of hyperproliferative dermatological diseases. These effects are mediated by specific nuclear receptor proteins that are members of the steroid and thyroid hormone receptor superfamily of transcriptional regulators. RARRES1, RARRES2, and RARRES3 are genes whose expression is upregulated by the synthetic retinoid tazarotene. RARRES3 is thought act as a tumor suppressor or growth regulator. [provided by RefSeq, Jul 2008]

retinoic acid receptor responder (tazarotene induced) 1

This gene was identified as a retinoid acid (RA) receptor-responsive gene. It encodes a type 1 membrane protein. The expression of this gene is upregulated by tazarotene as well as by retinoic acid receptors. The expression of this gene is found to be downregulated in prostate cancer, which is caused by the methylation of its promoter and CpG island. Alternatively spliced transcript variant encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008]

retinoic acid receptor responder protein 2 pseudogene

all-trans retinoic acid-induced differentiation factor

This gene is thought to be involved in apoptosis, and may also be involved in hematopoietic development and differentiation. The use of alternative splice sites and promotors result in multiple transcript variants encoding different isoforms.[provided by RefSeq, Dec 2009]

stimulated by retinoic acid 8

This gene encodes a retinoic acid-responsive protein. A homologous protein in mouse has been shown to be involved in the regulation of meiotic initiation in both spermatogenesis and oogenesis, though feature differences between the mouse and human proteins suggest that these homologs are not entirely functionally equivalent. It is thought that this gene may play a role in spermatogenesis in humans. [provided by RefSeq, Nov 2010]

bone morphogenetic protein/retinoic acid inducible neural-specific 3

This gene is overexpressed in pituitary tumors but is underexpressed in tongue squamous cell carcinomas, ulcerative colitis, and peri-implantitis. Polymorphisms that increase expression of this gene have been shown to increase vascular inflammation, and an association of this gene with myocardial infarction has been demonstrated. Finally, hypermethylation of this gene may find usefulness as a biomarker for gastric cancer. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2015]

bone morphogenetic protein/retinoic acid inducible neural-specific 2

Predicted to be involved in cellular response to retinoic acid; central nervous system neuron differentiation; and negative regulation of mitotic cell cycle. Predicted to act upstream of or within locomotion and nervous system development. Predicted to be located in extracellular region. Predicted to be active in cytoplasm; dendrite; and neuronal cell body. Implicated in oral squamous cell carcinoma. [provided by Alliance of Genome Resources, Mar 2025]

bone morphogenetic protein/retinoic acid inducible neural-specific 1

This gene is located within a chromosomal region that shows loss of heterozygosity in some bladder cancers. It contains a 5' CpG island that may be a frequent target of hypermethylation, and it may undergo hypermethylation-based silencing in some bladder cancers. [provided by RefSeq, Jul 2008]

retinoic acid early transcript 1K pseudogene

retinoic acid early transcript 1M pseudogene

retinoic acid induced 2

Retinoic acid plays a critical role in development, cellular growth, and differentiation. The specific function of this retinoic acid-induced gene has not yet been determined but it may play a role in development. The chromosomal location of this gene designates it to be a candidate for diseases such as Nance-Horan syndrome, sensorineural deafness, non-specific X-linked cognitive disability, oral-facial-digital syndrome, and Fried syndrome. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Feb 2010]

stimulated by retinoic acid 13

Enables DNA binding activity. Contributes to double-stranded DNA binding activity. Involved in interstrand cross-link repair; replication fork processing; and resolution of meiotic recombination intermediates. Part of chromosome and nucleus. [provided by Alliance of Genome Resources, Mar 2025]

retinoic acid receptor responder (tazarotene induced) 2 pseudogene 8

retinoic acid receptor responder (tazarotene induced) 2 pseudogene 2

retinoic acid receptor responder (tazarotene induced) 2 pseudogene 1

retinoic acid receptor responder (tazarotene induced) 2 pseudogene 4

retinoic acid early transcript 1E

This gene belong to the RAET1 family, which consists of major histocompatibility complex (MHC) class I-related genes located in a cluster on chromosome 6q24.2-q25.3. This and RAET1G protein differ from other RAET1 proteins in that they have type I membrane-spanning sequences at their C termini rather than glycosylphosphatidylinositol anchor sequences. This protein functions as a ligand for NKG2D receptor, which is expressed on the surface of several types of immune cells, and is involved in innate and adaptive immune responses. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Aug 2011]

retinoic acid early transcript 1G

This gene encodes a member of the major histocompatibility complex (MHC) class I family of proteins. Although the encoded protein includes C-terminal transmembrane and cytoplasmic domains, proteolytic processing results in the removal of these domains and subsequent tethering to the plasma membrane by a glycosylphosphatidylinositol (GPI)-anchor. The encoded protein is one of several related ligands of the natural killer group 2, member D (NKG2D) receptor, which functions as an activating receptor in innate and adaptive immunity. This gene is present in a gene cluster on chromosome 6. [provided by RefSeq, Jul 2015]

retinoic acid early transcript 1F pseudogene

retinoic acid early transcript 1L

RAET1L belongs to the RAET1 family of major histocompatibility complex (MHC) class I-related genes, which are located within a 180-kb cluster on chromosome 6q24.2-q25.3. The REAT1 genes encode glycoproteins that contain extracellular alpha-1 and alpha-2 domains, but they lack the membrane proximal Ig-like alpha-3 domain. Most RAET1 glycoproteins are anchored to the membrane via glycosylphosphatidylinositol (GPI) linkage (Radosavljevic et al., 2002 [PubMed 11827464]).[supplied by OMIM, Mar 2008]

retinoic acid induced 14

Predicted to enable actin binding activity. Predicted to be involved in cell differentiation and spermatogenesis. Located in cytosol; fibrillar center; and nucleoplasm. [provided by Alliance of Genome Resources, Mar 2025]

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_NCI-H460 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_NCI-H1792 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_NCI-H2347 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_NCI-H2030 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_NCI-H661 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_NCI-H596 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_NCI-H1573 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_NCI-H2122 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Oleic acid_NCI-H1792 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Salicylic acid_NCI-H1792 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Minodronic acid_NCI-H1792 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Salicylic acid_NCI-H661 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ferulic acid_NCI-H1792 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Folic acid_NCI-H2347 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Gallic acid_NCI-H1792 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Glycyrrhizic acid_NCI-H1792 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Folic acid_NCI-H1792 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Glycyrrhizic acid_NCI-H1573 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fumaric acid_NCI-H2030 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Minodronic acid_NCI-H2122 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fusidic acid_NCI-H596 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fumaric acid_NCI-H596 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lipoic acid_NCI-H1792 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Salicylic acid_NCI-H2347 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Oleic acid_NCI-H2122 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lipoic acid_NCI-H2347 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Oleic acid_NCI-H2347 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fusidic acid_NCI-H2030 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Minodronic acid_NCI-H2347 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Oleic acid_NCI-H661 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fusidic acid_NCI-H1573 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Folic acid_NCI-H2030 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fusidic acid_NCI-H2347 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ferulic acid_NCI-H2122 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_NCI-H2122 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Minodronic acid_NCI-H596 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Folic acid_NCI-H1573 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_NCI-H1792 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fusidic acid_NCI-H1792 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fumaric acid_NCI-H2347 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Glycyrrhizic acid_NCI-H2122 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Gallic acid_NCI-H661 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fumaric acid_NCI-H661 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Glycyrrhizic acid_NCI-H2347 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Gallic acid_NCI-H2347 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Minodronic acid_NCI-H2030 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Gallic acid_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ferulic acid_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Oleic acid_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Gallic acid_NCI-H1573 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fumaric acid_NCI-H1792 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Gallic acid_NCI-H2030 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fumaric acid_NCI-H1573 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Oleic acid_NCI-H2030 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Glycyrrhizic acid_NCI-H596 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Glycyrrhizic acid_NCI-H661 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_NCI-H2030 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Salicylic acid_NCI-H2122 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Salicylic acid_NCI-H2030 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Minodronic acid_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ferulic acid_NCI-H2030 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fusidic acid_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ferulic acid_NCI-H596 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Folic acid_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_NCI-H596 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lipoic acid_NCI-H2122 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Folic acid_NCI-H661 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ferulic acid_NCI-H1573 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Glycyrrhizic acid_NCI-H2030 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fumaric acid_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Oleic acid_NCI-H1573 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fumaric acid_NCI-H2122 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Minodronic acid_NCI-H1573 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Glycyrrhizic acid_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ferulic acid_NCI-H2347 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fusidic acid_NCI-H2122 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fusidic acid_NCI-H661 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Minodronic acid_NCI-H661 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ferulic acid_NCI-H661 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lipoic acid_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Folic acid_NCI-H2122 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_NCI-H2347 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Salicylic acid_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Salicylic acid_NCI-H596 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Salicylic acid_NCI-H1573 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lipoic acid_NCI-H596 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lipoic acid_NCI-H2030 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Gallic acid_NCI-H2122 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Folic acid_NCI-H596 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_NCI-H661 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lipoic acid_NCI-H1573 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_NCI-H1573 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Gallic acid_NCI-H596 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Oleic acid_NCI-H596 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lipoic acid_NCI-H661 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From CTD Gene-Chemical Interactions

genes/proteins interacting with the chemical 13-cis-12-(3'-carboxyphenyl)retinoic acid from the curated CTD Gene-Chemical Interactions dataset.

From CTD Gene-Chemical Interactions

genes/proteins interacting with the chemical 4-(1H-imidazol-1-yl)retinoic acid from the curated CTD Gene-Chemical Interactions dataset.

From GeneRIF Biological Term Annotations

genes co-occuring with the biological term retinoic in literature-supported statements describing functions of genes from the GeneRIF Biological Term Annotations dataset.

From GO Biological Process Annotations 2015

genes participating in the 9-cis-retinoic acid biosynthetic process biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the retinoic acid metabolic process biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the response to retinoic acid biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the retinoic acid biosynthetic process biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the 9-cis-retinoic acid metabolic process biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of retinoic acid biosynthetic process biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the retinoic acid receptor signaling pathway biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the retinoic acid catabolic process biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of retinoic acid receptor signaling pathway biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the cellular response to retinoic acid biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the negative regulation of retinoic acid receptor signaling pathway biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the positive regulation of retinoic acid receptor signaling pathway biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the negative regulation of retinoic acid biosynthetic process biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the retinoic acid 4-hydroxylase activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the retinoic acid-responsive element binding molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the retinoic acid receptor binding molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the 9-cis retinoic acid receptor activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the retinoic acid receptor activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the retinoic acid binding molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From Guide to Pharmacology Chemical Ligands of Receptors

receptors of the all-trans-4-oxo-retinoic acid ligand (chemical) from the curated Guide to Pharmacology Chemical Ligands of Receptors dataset.

From HMDB Metabolites of Enzymes

interacting proteins for the All-trans-retinoic acid metabolite from the curated HMDB Metabolites of Enzymes dataset.

From HMDB Metabolites of Enzymes

interacting proteins for the 9-cis-Retinoic acid metabolite from the curated HMDB Metabolites of Enzymes dataset.

From HMDB Metabolites of Enzymes

interacting proteins for the 13-cis-Retinoic acid metabolite from the curated HMDB Metabolites of Enzymes dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Retinoic acid receptor responder protein 2 protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Retinoic acid receptor responder protein 1 protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Retinoic acid receptor protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Retinoic acid-induced protein 2/sine oculis-binding protein homologue protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Retinoic acid induced 16-like protein protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Stimulated by retinoic acid gene 6 protein protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From Phosphosite Textmining Biological Term Annotations

proteins co-occuring with the biological term retinoic in abstracts of publications describing phosphosites from the Phosphosite Textmining Biological Term Annotations dataset.

From PID Pathways

proteins participating in the Retinoic acid receptors-mediated signaling pathway from the PID Pathways dataset.

From Reactome Pathways 2014

proteins participating in the Signaling by Retinoic Acid pathway from the Reactome Pathways dataset.

From DisGeNET Gene-Disease Associations

genes associated with the disease Retinoic Acid Syndrome in GWAS and other genetic association datasets from the DisGeNET Gene-Disease Associations dataset.

From GO Biological Process Annotations 2023

genes participating in the negative regulation of retinoic acid receptor signaling pathway biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Biological Process Annotations 2023

genes participating in the cellular response to retinoic acid biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Biological Process Annotations 2023

genes participating in the response to retinoic acid biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Biological Process Annotations 2023

genes participating in the retinoic acid catabolic process biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Biological Process Annotations 2023

genes participating in the retinoic acid receptor signaling pathway biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Biological Process Annotations 2023

genes participating in the negative regulation of retinoic acid biosynthetic process biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Biological Process Annotations 2023

genes participating in the retinoic acid biosynthetic process biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Biological Process Annotations 2023

genes participating in the positive regulation of retinoic acid receptor signaling pathway biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Biological Process Annotations 2023

genes participating in the regulation of retinoic acid receptor signaling pathway biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Biological Process Annotations 2023

genes participating in the 9-cis-retinoic acid biosynthetic process biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Biological Process Annotations 2023

genes participating in the regulation of retinoic acid biosynthetic process biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Biological Process Annotations 2023

genes participating in the 9-cis-retinoic acid metabolic process biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Molecular Function Annotations 2023

genes performing the nuclear retinoic acid receptor binding molecular function from the curated GO Molecular Function Annotations 2023 dataset.

From GO Molecular Function Annotations 2023

genes performing the retinoic acid binding molecular function from the curated GO Molecular Function Annotations 2023 dataset.

From GO Molecular Function Annotations 2023

genes performing the retinoic acid 4-hydroxylase activity molecular function from the curated GO Molecular Function Annotations 2023 dataset.

From GO Molecular Function Annotations 2023

genes performing the all-trans retinoic acid 18-hydroxylase activity molecular function from the curated GO Molecular Function Annotations 2023 dataset.

From GO Molecular Function Annotations 2023

genes performing the retinoic acid-responsive element binding molecular function from the curated GO Molecular Function Annotations 2023 dataset.

From GO Molecular Function Annotations 2023

genes performing the all-trans retinoic acid 3,4-desaturase activity molecular function from the curated GO Molecular Function Annotations 2023 dataset.

From MW Enzyme Metabolite Associations

interacting proteins for Retinoic acid metabolite from the MW Gene Metabolite Associations dataset.

From MW Enzyme Metabolite Associations

interacting proteins for 9-cis-Retinoic acid metabolite from the MW Gene Metabolite Associations dataset.

From WikiPathways Pathways 2024

proteins participating in the 4 hydroxytamoxifen dexamethasone and retinoic acids regulation of p27 expression pathway from the WikiPathways Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by Retinoic Acid pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation pathway from the Reactome Pathways 2024 dataset.

From GO Biological Process Annotations 2025

genes participating in the negative regulation of retinoic acid receptor signaling pathway biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Biological Process Annotations 2025

genes participating in the cellular response to retinoic acid biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Biological Process Annotations 2025

genes participating in the response to retinoic acid biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Biological Process Annotations 2025

genes participating in the retinoic acid catabolic process biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Biological Process Annotations 2025

genes participating in the retinoic acid metabolic process biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Biological Process Annotations 2025

genes participating in the retinoic acid receptor signaling pathway biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Biological Process Annotations 2025

genes participating in the negative regulation of retinoic acid biosynthetic process biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Biological Process Annotations 2025

genes participating in the retinoic acid biosynthetic process biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Biological Process Annotations 2025

genes participating in the positive regulation of retinoic acid receptor signaling pathway biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Biological Process Annotations 2025

genes participating in the regulation of retinoic acid receptor signaling pathway biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Biological Process Annotations 2025

genes participating in the 9-cis-retinoic acid biosynthetic process biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Biological Process Annotations 2025

genes participating in the regulation of retinoic acid biosynthetic process biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Biological Process Annotations 2025

genes participating in the 9-cis-retinoic acid metabolic process biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Molecular Function Annotations 2025

genes performing the nuclear retinoic acid receptor binding molecular function from the curated GO Molecular Function Annotations 2025 dataset.

From GO Molecular Function Annotations 2025

genes performing the retinoic acid binding molecular function from the curated GO Molecular Function Annotations 2025 dataset.

From GO Molecular Function Annotations 2025

genes performing the retinoic acid 4-hydroxylase activity molecular function from the curated GO Molecular Function Annotations 2025 dataset.

From GO Molecular Function Annotations 2025

genes performing the all-trans retinoic acid 18-hydroxylase activity molecular function from the curated GO Molecular Function Annotations 2025 dataset.

From GO Molecular Function Annotations 2025

genes performing the retinoic acid-responsive element binding molecular function from the curated GO Molecular Function Annotations 2025 dataset.

From GO Molecular Function Annotations 2025

genes performing the all-trans retinoic acid 3,4-desaturase activity molecular function from the curated GO Molecular Function Annotations 2025 dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_H4 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_A498 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_hTERT-HPNE drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_KATO III drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_AN3 CA drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_LS 180 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_SK-MEL-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_A-172 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_RPMI-7951 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_SW 900 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_CFPAC-1 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_Panc 03.27 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_HT-29 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_HEC-1-A drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_A549 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_AsPC-1 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_HepG2/C3A drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_SW1417 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_BT-474 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_SW 1271 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_C32 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_RKO drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_SW480 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_SW 1088 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_COLO 205 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_SNU-1 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_J82 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_CHP-212 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_HS-578T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_SHP-77 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_A-427 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_SNU-423 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_HOP62 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_PANC-1 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_C-33 A drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_LOX-IMVI drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_LoVo drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_HCT15 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_SW48 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From DGIdb Drug Targets 2026

interacting proteins for the ALL-TRANS-4-OXO-RETINOIC ACID drug from theDGIdb Drug Targets 2026 dataset.

From DGIdb Drug Targets 2026

interacting proteins for the RETINOIC ACID AGENT drug from theDGIdb Drug Targets 2026 dataset.